This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Future Clinical Trials. Genetically Driven Trials
Surgical Oncology Clinics of North America. 2017 Oct;26(4) :791-797
PMID: 28923231 PMCID: PMC5645064 URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027543498&doi=10.1016%2fj.soc.2017.05.014&partnerID=40&md5=210acee951fe9a00ad58412beb717e98
AbstractThe design of modern oncology clinical trials seeks to match patients' cancer molecular biomarkers with medications that specifically target those biomarkers, a general paradigm shift in cancer care coined clinical cancer biology. This approach exploits the synthetic lethality between a specific genetic alteration in the cancer cell and a drug: rapid termination of exaggerated kinase activity exemplifies this phenomenon. Synthetic lethality-based investigations are driven by rapidly evolving technologies for cancer molecular profiling. As these technologies evolve, future clinical trials will test drugs' activity based on the molecular mechanisms rather than by the tumor's appearance under a microscope.
NotesExport Date: 1 September 2017 Article in Press